Skip to content

The effect of methylene blue combined with ropivacaine for transversus abdominis plane block on postoperative analgesia in patients undergoing radical resection of colorectal cancer

The effect of methylene blue combined with ropivacaine for transversus abdominis plane block on postoperative analgesia in patients undergoing radical resection of colorectal cancer

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125533
Enrollment
Unknown
Registered
2026-05-28
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Methylene Blue Combined with Ropivacaine Group MR Group:The MR group received ultrasound-guided bilateral TAPB at the mid-axillary line level with a 20-ml solution of 0.375% ropivacaine plus 0.05% met
Ropivacaine Group R Group:Inject 20 ml of 0.375% ropivacaine hydrochloride injection on each side (7.5 ml of 1% ropivacaine hydrochloride + 12.5 ml of 0.9% sodium chloride injection). The total bilate

Sponsors

Shanxi Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Classified as ASA grade II~III by the American Society of Anesthesiologists (ASA); 2. Age between 18 and 75 years; 3. Body mass index (BMI) between 18 and 30 kg/m^2; 4. Each patient was preoperatively diagnosed with primary colorectal cancer, with no distant metastasis detected; 5. All surgeries were laparoscopic radical resections of rectal cancer, and all were sphincter-preserving procedures; 6. Surgery duration > 2 hours.

Exclusion criteria

Exclusion criteria: 1. BMI 30; ASA classification: Grade IV or above; 2. Patients with contraindications to nerve block, including coagulation abnormalities, severe infection at the puncture site or systemic infection, etc.; 3. Known allergy to related drugs; 4. Patients with certain neuromuscular system diseases; 5. Patients with higher intraocular pressure; 6. Long-term use of analgesics or antipsychotic drugs; 7. Patients who refuse to participate in the study; 8. Postoperative transfer to ICU, postoperative severe infection, or recurrence requiring secondary surgery; 9. Conversion from laparoscopic to open surgery; 10. Patients with severe complications or loss to follow-up.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale (VAS) Score;

Secondary

MeasureTime frame
opioid consumption;Inflammatory factor level;Immune cell subset count;First anal time;First time out of bed and active (hours);

Countries

China

Contacts

Public ContactZhang Weiwei, Chen Fujian

Shanxi Provincial People's Hospita

1069622779@qq.com+86 136 1346 9568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026